Internal Reference Number: FOI_6539
Date Request Received: 01/04/2022 00:00:00
Date Request Replied To: 06/04/2022 00:00:00
This response was sent via: By Email
Request Summary: Melanoma
Request Category: Private Individuals
| Question Number 1: In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with: 鈥� Bevacizumab (Avastin) 鈥� Dacarbazine (DTIC) 鈥� Trametinib (Mekinist) 鈥� Dabrafenib (Tafinlar) 鈥� Ipilimumab (Yervoy) 鈥� Vemurafenib (Zelboraf) 鈥� Nivolumab (Opdivo) 鈥� Nivolumab + Ipilimumab (Opdivo + Yervoy) 鈥� Pembrolizumab (Keytruda) 鈥� Vemurafenib + cobimetinib (Zelboraf + Cotellic) 鈥� Dabrafenib + Trametinib (Tafinlar + Mekinist) 鈥� Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients 鈥� Other active systemic anti-cancer therapy [please state] 鈥� Palliative care only | |
| Answer To Question 1: We do not treat this tumour group at this Trust so our answer is zero for all. | |
| Question Number 2: In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following: 鈥� Ipilimumab 鈥� Ipilimumab AND Nivolumab 鈥� Nivolumab 鈥� Pembrolizumab 鈥� Dabrafenib AND Trametinib 鈥� Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib) 鈥� Other active systemic anti-cancer therapy 鈥� Palliative care only | |
| Answer To Question 2: We do not treat this tumour group at this Trust so our answer is zero for all. | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of 看片软件 Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
